KLYV Therapeutics is an Oslo-based biotech developing small-molecule drugs that target the extracellular matrix to treat cardiac fibrosis and heart failure. The company had no website. We designed and built its first one in WordPress, turning complex science into a clear six-page story.
A drug discovery company has to be understood by very different readers: investors, potential partners, researchers and future colleagues. We structured the site so each of them can follow the science from the big idea to the evidence, without losing the precision the subject needs.
KLYV is developing a new treatment for cardiac fibrosis, a key driver of heart failure with preserved ejection fraction (HFpEF). The company had no website, so there was no shared place to explain the science, introduce the team or show progress.
We organized the site around the questions a visitor brings: what the technology is, how far the lead programme has come, who is behind the company and what has happened lately. The homepage gives a short entry to each, and the subpages go deeper.
The Technology page explains the extracellular matrix and KLYV’s discovery approach. Computational chemistry, medicinal chemistry and biological testing sit in tabs, and a pipeline table shows each programme’s stage from discovery towards clinical phases.
The Lead programme page moves from the medical problem to the target. Three evidence cards with scientific images sum up why the enzyme KLYV targets is relevant in heart failure.
Deep greens, network imagery and hexagonal frames give the site a calm, precise character. A floating navigation bar, gentle entrance animations and responsive layouts keep it easy to use on desktop and mobile.
KLYV now has a website that presents its science, team and progress in one place. When the company meets investors, partners or researchers, it has somewhere to send them, and the Updates page grows as the programme moves forward.
Let's talk about your project.
Trusted by 110+ businesses to grow online.
